Journal Article Review Epublish
PubMed: 40236366 DOI: 10.7759/cureus.80634
Infection Risk in Biological Disease-Modifying Anti-rheumatic Drugs.
Cureus 17(3):e80634
Authors: Mourushi Isa, Ma Rosario Rufina Ramos, Shahed Kamal
Affiliations
- General Medicine, Northern Health, Melbourne, AUS.
- Medicine, Ateneo School of Medicine and Public Health, Pasig, PHL.
Abstract
Rheumatology patients on biological disease-modifying anti-rheumatic drugs (bDMARDs) have been proposed to be at a higher risk of infections. Our review summarizes the current evidence behind this theory as well as explores which factors predispose patients to various infections, which agents are more likely to cause infections, and which infections are common in these patients. We also aim to explore updated guidelines on infection prevention in patients on bDMARDs.
MeSH
Immunization, Pharmaceutical Preparations, Antirheumatic Agents, Vaccination, Infections